Mitochon Pipeline

Compounds

MP101

Huntington’s Disease

Duchenne Muscular Dystrophy

Optic Neuritis

MP201

Multiple Sclerosis

Parkinson’s Disease

Pre-Clinical Efficacy

IND Enabling Activities

Phase I

Phase II

Mitochon Pharmaceuticals

Parkinson’s Disease

The Sirt3 KO mouse model, exhibits increased vulnerability of striatal and hippocampal neurons to degeneration.
6-OHDA in PBS injected into the right striatum of Sirt3 KO under stereotaxic guidance, the dopaminergic neurons are destroyed.
Prior to rotarod behavioral testing, MP101 was provided orally once per day for 14-days.

OUR DATA SHOWS:
MP101 Preserves Dopaminergic Neurons (TH+).
MP101 has a striking effect on behavior on the rotarod.

MP101 Preserves Dopaminergic Neurons (TH+).

6-OHDA model has selectively kill dopaminergic SN neurons slowly over the two weeks post-injection (ipsilateral side). The day after the injection the mice begin a two week treatment with MP101 at 1 and 5mpk, but the SN neurons are protected from eminent cell death (TH positive).

MP101 has a striking effect on behavior on the rotarod.

MP101 treated mice stay on the rotarod 4x longer than placebo.

Rotarod Test after 14-Days of Chronic Treatment with MP101 Showing Neuroprotection Against 6-OHDA-induced Degeneration of the Dopaminergic Neurons in the Nigrostriatal Pathway of Sirt3 KO mice.

Mitochon Pipeline

Compounds

MP101

MP201

No Widgets

Parkinson’s Disease

MP101 Preserves Dopaminergic Neurons (TH+).

MP101 has a striking effect on behavior on the rotarod.